Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors
April 11, 2017

  • Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumor microenvironment to demonstrate enhanced anti-tumor activity
  • Study to enroll second-line metastatic non-small cell lung cancer (NSCLC) patients who have failed prior chemotherapy and metastatic melanoma patients who have failed prior I-O therapy

(San Carlos, CA and NEW YORK – April 11, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology (I-O) agents, today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Apexigen’s APX005M in patients with advanced solid tumors. APX005M is an investigational compound that is designed to activate CD40, a key immune co-stimulatory receptor essential to regulating the activation of both innate and adaptive immune responses against cancer.

The proposed collaboration will evaluate the safety, tolerability and preliminary efficacy of APX005M in combination with Opdivo in second-line metastatic NSCLC patients who have failed prior chemotherapy, and in metastatic melanoma patients who have failed prior I-O therapy.

Preclinical data suggest that APX005M mimics the endogenous immune activation process through activation of CD40. A receptor on the surface of antigen presenting cells of the immune system, CD40 plays a fundamental role in the activation of both innate and adaptive immune system mechanisms. Opdivo is designed to overcome PD-1 pathway related immune suppression. The companies will explore the potential of combining these two agents with the goal of effectively activating antigen presenting cells (APC) in the tumor microenvironment, thus driving a more productive and sustained immune response against the tumor.

“Targeting the tumor microenvironment through activation of antigen-presenting cells is a novel approach that we are excited to add to our Immuno-Oncology strategy as we continue to advance research for cancers with limited treatment options,” stated Fouad Namouni, M.D., Head of Oncology Development, Bristol-Myers Squibb. “Our agreement with Apexigen builds on our continued focus to bring forward potential novel combination treatment options for patients with cancer.”

“APX005M has demonstrated immune stimulation in patients with solid tumors in a Phase 1 study,” said Xiaodong Yang, M.D., Ph.D., President and CEO of Apexigen. “Based on scientific rationale and demonstrated data, we are excited about the new combination studies with Opdivo and APX005M.”

Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world in July 2014, and currently has regulatory approval in 57 countries including the United States, Japan, and in the European Union.

APX005M is a novel, humanized investigational monoclonal antibody designed to reverse the systemic immune suppression that typically affects cancer patients. APX005M is designed to activate CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems.

Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.
浙江20选5预测推荐 怎么跟ag真人平台合作 博格体育网-体育赛事资讯网站 bg视讯跟ag视讯哪个好一点 上海时时乐走势 河内5分彩后三直选彩经网 江西多乐彩投注技巧 手机比分直播 闵乐游棋牌 南方网双色球综合分布图号码 黑龙江22选5胆拖玩法 平特一肖大公开免费平码 黑龙江11选5开奖结果zhw 天津体彩泳坛夺金开奖 emba报考条件及费用 信和贷理财平台 山东麻将258四人麻将